Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2421-2428

  Fish, Douglas N ^a   Teitelbaum, Isaac ^a   Abraham, Edward ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN; DOPAMINE; IMIPENEM; NORADRENALIN; PHENYLEPHRINE; VASOPRESSIN;

ACINETOBACTER BAUMANNII; ACUTE HEMORRHAGIC PANCREATITIS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SEPSIS; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; ULTRAFILTRATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CILASTATIN; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; IMIPENEM; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RENAL REPLACEMENT THERAPY;

EID: 19544381372     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2421-2428.2005     Document Type: Article

References (43)

1. Bodenham, A., M. P. Shelly, and G. R. Park. 1988. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin. Pharmacokinet. 14:347-373.
2. Bressolle, F., J. Kinowski, J. E. de la Coussaye, N. Wynn, J. Eledjam, and M. Galtier. 1994. Clinical pharmacokinetics during continuous haemofiltration. Clin. Pharmacokinet. 26:457-471.
3. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
5. Drusano, G. L., H. C. Standiford, C. Bustamante, A. Forrest, G. Rivera, J. Leslie, B. Tatem, D. Delaportas, R. R. MacGregor, and S. C. Schimpff. 1984. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob. Agents Chemother. 26:715-721.
6. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36(Suppl. 1):S42-S50.
7. Forni, L. G., and P. J. Hilton. 1997. Continuous hemofiltration in the treatment of acute renal failure. N. Engl. J. Med. 336:1303-1309.
8. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2001. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1915-1918.
9. Gibson, T. P., J. L. Demetriades, and J. A. Bland. 1985. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am. J. Med. 78(Suppl. 6A): 54-61.
10. Gilbert, D. N., R. C. Moellering Jr., G. M. Eliopoulos, and M. A. Sande (editors). 2004. The Sanford guide to antimicrobial therapy, 34th ed. Antimicrobial Therapy, Inc., Hyde Park, Vt.
11. Giles, L. J., A. C. Jennings, A. H. Thomson, G. Creed, R. J. Beale, and A. McLuckie. 2000. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit. Care Med. 28:632-637.
12. Golper, T. A. 1991. Drug removal during continuous hemofiltration or hemodialysis. Contrib. Nephrol. 93:110-116.
13. Gravallese, D. A., D. G. Musson, L. T. Pauliukonis, and F. W. Bayne. 1984. Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability. J. Chromatogr. 310:71-84.
14. Hashimoto, S., M. Honda, M. Yamaguchi, M. Sekimoto, and Y. Tanaka. 1997. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ASAIO J. 43:84-88.
15. Janmohamed, R. M., M. J. Leyland, J. Kelly, and I. Farrell. 1990. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. J. Antimicrob. Chemother. 25:407-412.
16. Jones, E. M., C. M. McMullin, A. J. Hedges, A. M. Levering, L. O. White, D. S. Reeves, and A. P. MacGowan. 1997. The pharmacokinetics of intravenous ciprofloxacin 400 mg every 12 hours in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J. Antimicrob. Chemother. 40:121-124.
17. Joy, M. S., G. R. Matzke, D. K. Armstrong, M. A. Marx, and B. J. Zarowitz. 1998. A primer on continuous renal replacement therapy for critically ill patients. Ann. Pharmacother. 32:362-375.
18. Karlowsky, J. A., D. C. Draghi, M. E. Jones, C. Thornsberry, I. R. Friedland, and D. F. Sahm. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688.
19. Keller, E., H. Fecht, J. Bohler, and P. Schollmeyer. 1989. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol. Dial. Transplant. 4:640-645.
20. Livermore, D. M., M. W. Carter, S. Bagel, B. Wiedemann, F. Baquero, E. Loza, H. P. Endtz, N. van den Braak, C. J. Fernandes, L. Fernandes, N. Frimodt-Moller, L. S. Rasmussen, H. Giamarellou, E. Giamarellous-Bourboulis, V. Jarlier, J. Nguyen, C.-E. Nord, M. J. Struelens, C. Nonhoff, J. Turnidge, J. Bell, R. Zbinden, S. Pfister, L. Mixson, and D. L. Shungu. 2001. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob. Agents Chemother. 45:1860-1867.
21. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
22. MacGregor, R. R., G. A. Gibson, and J. A. Bland. 1986. Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. Antimicrob. Agents Chemother. 29:188-192.
23. Malone, R. S., D. N. Fish, E. Abraham, and I. Teitelbaum. 2001. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother. 45: 2949-2954.
24. Malone, R. S., D. N. Fish, E. Abraham, and I. Teitelbaum. 2001. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother. 45:3148-3155.
25. Mueller, B. A., S. K. Scarim, and W. L. Macias. 1993. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am. J. Kidney Dis. 21:172-179.
26. National Nosocomial Infections Surveillance System 1999. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532.
27. Neuhauser, M. M., R. A. Weinstien, R. Rydman, L. H. Danziger, G. Karam, and J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 289:885-888.
28. Nilsson-Ehle, I., M. Hutchison, S. J. Haworth, and S. R. Norrby. 1991. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10:85-88.
29. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2004. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48:4606-4610.
30. Pfaller, M. A., R. N. Jones, and D. J. Biedenbach. 2001. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41:177-182.
31. Power, B. M., A. M. Forbes, P. V. Heerden, and K. F. Ilett. 1998. Pharmacokinetics of drugs used in critically ill adults. Clin. Pharmacokinet. 34:25-56.
32. Przechera, M., D. Bengel, and T. Risler. 1991. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration. Contrib. Nephrol. 93:131-134.
33. Reetze-Bonorden, P., J. Bohler, and E. Keller. 1993. Drug dosing in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin. Pharmacokinet. 24:362-379.
34. Ronco, C., R. Bellomo, and Z. Ricci. 2001. Continuous renal replacement therapy in critically ill patients. Nephrol. Dial. Transplant. 16(Suppl. 5): 67-72.
35. Schetz, M., P. Ferdinande, R. Van den Berghe, C. Verwaest, and P. Lauwers. 1995. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 21:612-620.
36. Shargel, L., and A. B. C. Yu. 1999. Applied biopharmaceutics and pharmacokinetics, 4th ed. Appleton & Lange, Stamford, Conn.
37. Smith, G. B., G. C. Dezeny, and A. W. Douglas. 1990. Stability and kinetics of degradation of imipenem in aqueous solution. J. Pharm. Sci. 79:732-740.
38. Tegeder, I., F. Bremer, R. Oelkers, H. Schobel, J. Schüttler, K. Brune, and G. Geisslinger. 1997. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob. Agents Chemother. 41:2640-2645.
39. Turnidge, J. D. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22.
40. Van Dalen, R., and T. B. Vree. 1990. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 16(Suppl. 3):S235-S238.
41. Verbist, L., G. A. Verpooten, R. A. Guiliano, M. E. Debroe, A. P. Buntinx, L. A. Entwistle, and K. H. Jones. 1986. Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure. J. Antimicrob. Chemother. 18(Suppl. E):115-120.
42. Verpooten, G. A., L. Verbist, A. P. Buntinx, L. A. Entwistle, K. H. Jones, and M. E. De Broe. 1984. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br. J. Clin. Pharmacol. 18: 183-193.
43. Vos, M. C., H. H. Vincent, and E. P. F. Yzerman. 1992. Clearance of imipenem/cilastatin in acute renal failrure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med. 18:282-285.